BUZZ-Abivax rises as another media report feeds M&A chatter

Reuters01-20 16:56
BUZZ-Abivax rises as another media report feeds M&A chatter

** Shares of French inflammatory-disease specialist Abivax ABVX.PA rise 6%, paring earlier gains of about 8%; analysts link the rise in a generally volatile stock to another media report stoking M&A chatter

** Analysts at Kepler Chevreux and ODDO BHF link the rise to a La Lettre report that British pharma group AstraZeneca AZN.L offered around 176 euros ($205.85) per Abivax share at the end of 2025

** Abivax has been recently surrounded by increased M&A chatter

** La Lettre earlier reported that rival Eli Lilly LLY.N was preparing a 15 billion euro ($17.5 billion) bid, but France's Finance Ministry said it had not received any formal request for investment approval

** AstraZeneca and Abivax were not immediately available for a comment

($1 = 0.8550 euros)

(Reporting by Nathan Vifflin in Gdansk)

((nathan.vifflin@thomsonreuters.com; +48 58 769 67 13;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment